Many questions surround new Alzheimer’s treatment

March 25, 2015 12:57 AM

6 0

Many questions surround new Alzheimer’s treatment

Though a new drug may be able to treat early stage Alzheimer’s, this may not be as good as it originally seems.

Biogen, a Cambridge, Massachusetts biotech company is behind the drug (aducanumab) that acts as a monoclonal antibody, NBC News reports. The drug has shown impressive results in early tests on those with early stage Alzheimer’s disease, and it has also significantly reduced the amyloid plaque buildu...

Also read: Apple tells feds ‘new entrants’ to auto industry should get same testing rights as incumbents

Read more

To category page

Loading...